US

Sergio Finkeilsztein

This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.


Average Co-Inventor Count = 1.0

ph-index = 1


Loading Chart...

Title: Sergio Finkeilsztein: Innovator in Vascular Modulation

Introduction

Sergio Finkeilsztein is an accomplished inventor based in the United States. He has made significant contributions to the field of vascular health through his innovative research and development. His work focuses on compositions and methods that modulate vascular structure and function.

Latest Patents

Sergio Finkeilsztein holds a patent titled "Compositions And Methods For Modulation Of Vascular Structure And/or Function." This invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing these polymers for the modulation of vascular structure and function. The compositions and methods disclosed are useful for stimulating endothelin-1 release, vasoconstriction, and reducing blood flow out of a breached vessel. They also contribute to the cessation of bleeding. The methods involve the topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins and substantially free of single amino acids and other contaminants.

Career Highlights

Sergio Finkeilsztein has been associated with Marine Polymer Technologies, Inc., where he has applied his expertise in polymer science to develop innovative solutions for vascular health. His work has been instrumental in advancing the understanding of how specific polymers can influence vascular responses.

Collaborations

Sergio has collaborated with John N. Vournakis, a fellow researcher, to further explore the applications of his inventions in the medical field.

Conclusion

Sergio Finkeilsztein is a notable inventor whose work in vascular modulation has the potential to impact medical treatments significantly. His innovative approaches and dedication to research continue to pave the way for advancements in vascular health.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…